title: Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.
authors.affiliation: Department I for Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, D-50937 Cologne, Germany. sebastian.theurich@uk-koeln.de
authors.forename: Sebastian
authors.initials: S
authors.lastname: Theurich
authors.forename: Joke
authors.initials: J
authors.lastname: Malcher
authors.forename: Kerstin
authors.initials: K
authors.lastname: Wennhold
authors.forename: Alexander
authors.initials: A
authors.lastname: Shimabukuro-Vornhagen
authors.forename: Jens
authors.initials: J
authors.lastname: Chemnitz
authors.forename: Udo
authors.initials: U
authors.lastname: Holtick
authors.forename: Anke
authors.initials: A
authors.lastname: Krause
authors.forename: Carsten
authors.initials: C
authors.lastname: Kobe
authors.forename: Deniz
authors.initials: D
authors.lastname: Kahraman
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Christof
authors.initials: C
authors.lastname: Scheid
authors.forename: Geothy
authors.initials: G
authors.lastname: Chakupurakal
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.forename: Michael
authors.initials: M
authors.lastname: von Bergwelt-Baildon
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017209:Apoptosis / Q000276:immunology*; D000079963:Brentuximab Vedotin; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006086:Graft vs Host Disease / Q000209:etiology; D015789:HLA-A2 Antigen / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006689:Hodgkin Disease / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016219:Immunotherapy, Adoptive / Q000379:methods; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors*; D008214:Lymphocytes / Q000276:immunology*; D055651:NK Cell Lectin-Like Receptor Subfamily B / Q000276:immunology; D011115:Polyneuropathies / Q000139:chemically induced; D012008:Recurrence; D012074:Remission Induction; D012772:Shock, Septic / Q000209:etiology; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology; D013921:Thrombocytopenia / Q000139:chemically induced; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015789:HLA-A2 Antigen; D018796:Immunoconjugates; C527203:KLRB1 protein, human; D017730:Ki-1 Antigen; D055651:NK Cell Lectin-Like Receptor Subfamily B; D000079963:Brentuximab Vedotin